Open AccessPrognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab
Author(s) -
Taro Ohba,
Shinkichi Takamori,
Ryo Toyozawa,
Kaname Nosaki,
Yasuhiro Umeyama,
Naoki Haratake,
Naruhisa Miura,
Masafumi Yamaguchi,
Kenichi Taguchi,
Takashi Seto,
Mototsugu Shimokawa,
Mitsuhiro Takenoyama
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.09.29
Subject(s) - pembrolizumab , medicine , lung cancer , oncology , multivariate analysis , univariate analysis , univariate , immunotherapy , cancer , multivariate statistics , statistics , mathematics
Pembrolizumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody, has been shown to yield a durable response and significant survival benefit in some non-small cell lung cancer (NSCLC) patients. Recent studies have shown that the Controlling Nutritional Status (CONUT) score, a novel nutritional index, can be useful for predicting the prognosis in some malignancies. However, its usefulness in predicting the clinical outcome of immune-checkpoint inhibitor (ICI) treatment in patients with NSCLC has not been clarified. The aim of this study was to investigate the clinical significance of the CONUT score in NSCLC patients treated with pembrolizumab.